Marker Therapeutics, Inc.
MRKR
$1.42
-$0.04-2.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -10.50% | 43.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -10.50% | 43.16% | |||
| Cost of Revenue | -8.74% | -43.84% | |||
| Gross Profit | 6.78% | 66.44% | |||
| SG&A Expenses | -17.31% | 8.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.35% | -34.21% | |||
| Operating Income | 11.83% | 49.85% | |||
| Income Before Tax | 14.02% | 50.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.78% | 50.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.78% | 50.23% | |||
| EBIT | 11.83% | 49.85% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 26.24% | 58.53% | |||
| Normalized Basic EPS | 25.50% | 58.57% | |||
| EPS Diluted | 26.67% | 58.62% | |||
| Normalized Diluted EPS | 25.50% | 58.57% | |||
| Average Basic Shares Outstanding | 15.52% | 20.07% | |||
| Average Diluted Shares Outstanding | 15.52% | 20.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||